Roman - That's why I don't see conventional GIA launch to achieve ultimate BO price. The magnitude of the opportunity is too big, and still, with yet to pursue combos and DCVax-D, from a time horizon aspect and financial cost renders the idea impractical. So that leaves franchise/licensing in some shape or form, as the vehicle that could lead to such price discovery.
The value is only for cancer. I put a multiplier on your number if I want to include the fields like antiviral, antibacteria, antifungus, autoimmune diseases.